Verona Pharma Plc ADR (VRNA)

$106.27 -0.10 (-0.09%)
Market Cap 8.70B
Revenue (ttm) 42.28M
Net Income (ttm) -173.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 477.57
Profit Margin -410.17%
Debt to Equity Ratio 0.87
Volume 1,456,500
Avg Vol 4,082,016
Day's Range N/A - N/A
Shares Out 81.83M
Stochastic %K 60%
Beta 0.14
Analysts Sell
Price Target $106.22

Company Profile

Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma. Verona Pharma plc was incorporated in 2005 an...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 20 3283 4200
Address:
3 More London Riverside, London, United Kingdom
Dark_Horse_Investments
Dark_Horse_Investments Sep. 16 at 6:51 PM
$VRNA voted NO, NO, YES. hold 70% of position (just under 10k shares)
0 · Reply
DipinDipout
DipinDipout Sep. 16 at 2:10 PM
$VRNA will shares be converted to Merck (adjusted for price) or pure cash exchange @ 107.00 close out. I’m still holding 40,000 shares @ around 12.00.
2 · Reply
JimmyBoomBoom
JimmyBoomBoom Sep. 14 at 5:41 PM
Look to see where there is unmet need. Saw steroid-free alternatives for autoimmune diseases ($CCXI) and COPD ($VRNA). Huge unmet need for metabolic Liver diseases ($MDGL) and Alzheimer's Disease ($AVXL) not requiring costly and inconvenient injections.
3 · Reply
biotrader2324
biotrader2324 Sep. 12 at 5:48 PM
$TARS eerily similar to $VRNA shortly before it was bought out. About a 19% move from peak to trough in May then continued on a steep uptrend and eventual buyout. Today we just hit a 19% move from peak to trough as well if today's low holds as the low.
1 · Reply
Ms_P
Ms_P Sep. 12 at 5:08 PM
$VRNA Last chance to get into $ATYR
1 · Reply
Kingjake26
Kingjake26 Sep. 11 at 9:05 PM
$TNXP my friends from $VRNA Take a look at this one as well. This could be a nice opportunity. Here. What's particularly noteworthy is Tonmya's novel mechanism targeting non-restorative sleep through receptor antagonism affecting sleep architecture. This approach addresses the multifaceted nature of fibromyalgia by improving not just pain, but also sleep disturbance and fatigue – core symptoms that significantly impact patient quality of life. This comprehensive symptom management could differentiate Tonmya from existing treatments.
1 · Reply
FE123
FE123 Sep. 10 at 6:50 PM
$IOVA Forget that Crook Rothbaum come over to $VKTX with Stanley Druckenmiller for the Buyout! His last 2 Positions had Buyouts in the Past 6 Months $VRNA $SWTX $VKTX by year End!
0 · Reply
Rascal7777777
Rascal7777777 Sep. 10 at 6:20 AM
$VRNA sold out of 2/3 accounts with VRNA. One more left. Need to roll it into a Sweet position somewhere!
1 · Reply
FE123
FE123 Sep. 9 at 11:05 PM
$VKTX Druckenmiller past 6 Months! $VRNA Buyout! $SWTX Buyout! $VKTX Buyout by year end!
1 · Reply
StonkFactor
StonkFactor Sep. 8 at 6:53 PM
$VRNA why did this stop running.. i cant believe this is at 100 shouldve bought n held at 30$
2 · Reply
Latest News on VRNA
Verona Pharma to Present Additional Analyses of the Phase 3 ENHANCE Studies in COPD at ERS International Congress 2025

Sep 16, 2025, 6:00 AM EDT - 18 hours ago

Verona Pharma to Present Additional Analyses of the Phase 3 ENHANCE Studies in COPD at ERS International Congress 2025

VERONA PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verona Pharma plc - VRNA

Jul 12, 2025, 9:09 PM EDT - 2 months ago

VERONA PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verona Pharma plc - VRNA

MRK

Major deals involving U.S. drugmakers and biotechs over the past decade

Jul 9, 2025, 1:46 PM EDT - 2 months ago

Major deals involving U.S. drugmakers and biotechs over the past decade

MRK

Merck to Buy Verona Pharma for Around $10 Billion

Jul 9, 2025, 12:36 PM EDT - 2 months ago

Merck to Buy Verona Pharma for Around $10 Billion

MRK

Two big reasons why buying Verona was crucial for Merck

Jul 9, 2025, 10:38 AM EDT - 2 months ago

Two big reasons why buying Verona was crucial for Merck

Merck has struck a roughly $10 billion deal to buy Verona Pharma

Jul 9, 2025, 10:36 AM EDT - 2 months ago

Merck has struck a roughly $10 billion deal to buy Verona Pharma

MRK

Verona Pharma shares jump with Merck set to acquire company in $10 billion deal

Jul 9, 2025, 8:13 AM EDT - 2 months ago

Verona Pharma shares jump with Merck set to acquire company in $10 billion deal

Merck dives into COPD treatments with $10 billion purchase of Verona Pharma

Jul 9, 2025, 7:48 AM EDT - 2 months ago

Merck dives into COPD treatments with $10 billion purchase of Verona Pharma

MRK

Verona Pharma Stock Jumps 21%. It's Being Bought for $10 Billion by Merck.

Jul 9, 2025, 7:14 AM EDT - 2 months ago

Verona Pharma Stock Jumps 21%. It's Being Bought for $10 Billion by Merck.

MRK

Merck to Buy Verona Pharma in $10 Billion Deal

Jul 9, 2025, 6:48 AM EDT - 2 months ago

Merck to Buy Verona Pharma in $10 Billion Deal

MRK

Merck to acquire Verona Pharma for $10 billion

Jul 9, 2025, 6:39 AM EDT - 2 months ago

Merck to acquire Verona Pharma for $10 billion

MRK

Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade

Jul 9, 2025, 6:30 AM EDT - 2 months ago

Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade

MRK

Merck nears $10 billion deal for respiratory drugmaker Verona, FT reports

Jul 9, 2025, 1:09 AM EDT - 2 months ago

Merck nears $10 billion deal for respiratory drugmaker Verona, FT reports

MRK

Verona Pharma: A Blockbuster Franchise In The Making

Jun 10, 2025, 1:17 AM EDT - 3 months ago

Verona Pharma: A Blockbuster Franchise In The Making

Mizuho's Jared Holz details potential biotech, pharma acquisitions

Jun 4, 2025, 6:10 PM EDT - 3 months ago

Mizuho's Jared Holz details potential biotech, pharma acquisitions

INSM LEGN

Verona Pharma Announces June 2025 Investor Conference Participation

May 21, 2025, 6:00 AM EDT - 4 months ago

Verona Pharma Announces June 2025 Investor Conference Participation

Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025

May 6, 2025, 6:00 AM EDT - 4 months ago

Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025

Silencing The Doubters: Verona Pharma Could Be Sitting On A Blockbuster

May 1, 2025, 8:51 AM EDT - 4 months ago

Silencing The Doubters: Verona Pharma Could Be Sitting On A Blockbuster

Verona Pharma plc (VRNA) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 3:45 PM EDT - 5 months ago

Verona Pharma plc (VRNA) Q1 2025 Earnings Call Transcript

Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 29, 2025, 6:00 AM EDT - 5 months ago

Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

Verona Pharma's Bull Case Holds, But Lifecycle Extension Is Critical

Apr 7, 2025, 10:47 AM EDT - 5 months ago

Verona Pharma's Bull Case Holds, But Lifecycle Extension Is Critical

Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS

Mar 28, 2025, 7:00 AM EDT - 6 months ago

Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS

Verona Pharma plc (VRNA) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 2:31 PM EST - 7 months ago

Verona Pharma plc (VRNA) Q4 2024 Earnings Call Transcript

Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Feb 27, 2025, 6:00 AM EST - 7 months ago

Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Verona Pharma Announces March 2025 Investor Conference Participation

Feb 18, 2025, 6:00 AM EST - 7 months ago

Verona Pharma Announces March 2025 Investor Conference Participation

Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update

Feb 13, 2025, 6:00 AM EST - 7 months ago

Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update

Verona Pharma's Ohtuvayre Defies Expectations In Q4, But Stock Alpha May Now Be Limited

Jan 8, 2025, 1:45 PM EST - 8 months ago

Verona Pharma's Ohtuvayre Defies Expectations In Q4, But Stock Alpha May Now Be Limited

Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights

Jan 7, 2025, 6:00 AM EST - 9 months ago

Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights

Verona Pharma Announces December 2024 Investor Conference Participation

Nov 19, 2024, 2:00 AM EST - 10 months ago

Verona Pharma Announces December 2024 Investor Conference Participation

Caligan picks up a stake in Verona Pharma, seeing an opportunity to generate more value

Nov 9, 2024, 8:23 AM EST - 11 months ago

Caligan picks up a stake in Verona Pharma, seeing an opportunity to generate more value

Verona Pharma to Present at Jefferies London Healthcare Conference

Nov 5, 2024, 2:00 AM EST - 11 months ago

Verona Pharma to Present at Jefferies London Healthcare Conference

Verona Pharma plc (VRNA) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 11:47 AM EST - 11 months ago

Verona Pharma plc (VRNA) Q3 2024 Earnings Call Transcript

Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 4, 2024, 2:00 AM EST - 11 months ago

Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Oct 21, 2024, 2:00 AM EDT - 11 months ago

Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

Oct 8, 2024, 5:00 AM EDT - 1 year ago

Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

ENTO OCS ONCO

Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024

Sep 30, 2024, 2:00 AM EDT - 1 year ago

Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024

Verona Pharma's Ohtuvayre Set To Unlock Significant Value In COPD Care

Sep 14, 2024, 4:20 AM EDT - 1 year ago

Verona Pharma's Ohtuvayre Set To Unlock Significant Value In COPD Care

Verona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024

Sep 5, 2024, 2:00 AM EDT - 1 year ago

Verona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024

Top 3 Health Care Stocks That May Crash In August

Aug 14, 2024, 8:35 AM EDT - 1 year ago

Top 3 Health Care Stocks That May Crash In August

CAH CPRX

Verona Pharma plc (VRNA) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 1:15 PM EDT - 1 year ago

Verona Pharma plc (VRNA) Q2 2024 Earnings Call Transcript

Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 8, 2024, 2:00 AM EDT - 1 year ago

Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Top 3 Health Care Stocks You May Want To Dump This Quarter

Jul 30, 2024, 10:13 AM EDT - 1 year ago

Top 3 Health Care Stocks You May Want To Dump This Quarter

CPRX VRDN

Verona Pharma to Present at 44th Annual Canaccord Growth Conference

Jul 30, 2024, 2:00 AM EDT - 1 year ago

Verona Pharma to Present at 44th Annual Canaccord Growth Conference

Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Jul 25, 2024, 2:00 AM EDT - 1 year ago

Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Verona Pharma Is Launching Ohtuvayre, Although There Will Be Competition

Jun 30, 2024, 9:00 AM EDT - 1 year ago

Verona Pharma Is Launching Ohtuvayre, Although There Will Be Competition

First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product

Jun 27, 2024, 9:49 AM EDT - 1 year ago

First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product

Verona Pharma's inhaled COPD therapy to be priced at $2,950 per month

Jun 27, 2024, 9:03 AM EDT - 1 year ago

Verona Pharma's inhaled COPD therapy to be priced at $2,950 per month

US FDA approves Verona Pharma's therapy for 'smoker's lungs'

Jun 26, 2024, 5:13 PM EDT - 1 year ago

US FDA approves Verona Pharma's therapy for 'smoker's lungs'

Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)

Jun 26, 2024, 4:57 PM EDT - 1 year ago

Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)

Dark_Horse_Investments
Dark_Horse_Investments Sep. 16 at 6:51 PM
$VRNA voted NO, NO, YES. hold 70% of position (just under 10k shares)
0 · Reply
DipinDipout
DipinDipout Sep. 16 at 2:10 PM
$VRNA will shares be converted to Merck (adjusted for price) or pure cash exchange @ 107.00 close out. I’m still holding 40,000 shares @ around 12.00.
2 · Reply
JimmyBoomBoom
JimmyBoomBoom Sep. 14 at 5:41 PM
Look to see where there is unmet need. Saw steroid-free alternatives for autoimmune diseases ($CCXI) and COPD ($VRNA). Huge unmet need for metabolic Liver diseases ($MDGL) and Alzheimer's Disease ($AVXL) not requiring costly and inconvenient injections.
3 · Reply
biotrader2324
biotrader2324 Sep. 12 at 5:48 PM
$TARS eerily similar to $VRNA shortly before it was bought out. About a 19% move from peak to trough in May then continued on a steep uptrend and eventual buyout. Today we just hit a 19% move from peak to trough as well if today's low holds as the low.
1 · Reply
Ms_P
Ms_P Sep. 12 at 5:08 PM
$VRNA Last chance to get into $ATYR
1 · Reply
Kingjake26
Kingjake26 Sep. 11 at 9:05 PM
$TNXP my friends from $VRNA Take a look at this one as well. This could be a nice opportunity. Here. What's particularly noteworthy is Tonmya's novel mechanism targeting non-restorative sleep through receptor antagonism affecting sleep architecture. This approach addresses the multifaceted nature of fibromyalgia by improving not just pain, but also sleep disturbance and fatigue – core symptoms that significantly impact patient quality of life. This comprehensive symptom management could differentiate Tonmya from existing treatments.
1 · Reply
FE123
FE123 Sep. 10 at 6:50 PM
$IOVA Forget that Crook Rothbaum come over to $VKTX with Stanley Druckenmiller for the Buyout! His last 2 Positions had Buyouts in the Past 6 Months $VRNA $SWTX $VKTX by year End!
0 · Reply
Rascal7777777
Rascal7777777 Sep. 10 at 6:20 AM
$VRNA sold out of 2/3 accounts with VRNA. One more left. Need to roll it into a Sweet position somewhere!
1 · Reply
FE123
FE123 Sep. 9 at 11:05 PM
$VKTX Druckenmiller past 6 Months! $VRNA Buyout! $SWTX Buyout! $VKTX Buyout by year end!
1 · Reply
StonkFactor
StonkFactor Sep. 8 at 6:53 PM
$VRNA why did this stop running.. i cant believe this is at 100 shouldve bought n held at 30$
2 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Sep. 8 at 12:49 AM
The attached graph compares $CORT analyst consensus revenue estimates for FY25 - FY34 to the revenue forecasts prepared by ITCI, $VRNA & $BPMC management/BOD, over the same 10 year period, when they were acquired earlier in FY2025. CORT's revenue forecast appears roughly consistent with the 3 peers acquired earlier this year at roughly the same gross margin profile. CORT trades at 0.27X their 10-year analyst consensus where the 3 peers were acquired at 0.36X to 0.41X. We know the PDUFA for Relacorilant in Cushing's Syndrome = 12/30/2025. Can any CORT investor share then the data read is expected in platinum resistant ovarian cancer? This is not investment advice.
5 · Reply
Rungreen
Rungreen Sep. 6 at 3:01 PM
$VRNA anyone buying MRK? They have a 5 year upside of 84%, or $140 plus a healthy dividend.
2 · Reply
FE123
FE123 Sep. 5 at 7:19 PM
$VKTX Druckenmiller has 550,000 Shares currently! He went over 1 Million shares of $VRNA ! Expect him to go over 1 million shares at $VKTX for the Buyout!
1 · Reply
Ms_P
Ms_P Sep. 5 at 2:39 PM
$CRNX Buying more, nice to be in a space again that isn’t flooded by biased/overly pessimistic bears. Reminds me $VRNA all last year! 🙂
1 · Reply
FE123
FE123 Sep. 4 at 6:08 PM
$SWTX $VRNA Druckenmiller Positions that had Buyouts in last 6 Months! $VKTX Next by Christmas!
1 · Reply
Zip74
Zip74 Sep. 4 at 1:48 PM
$VRNA Have any UK based investors in VRNA received any voting correspondence as yet? I’ll be voting NO to the merger if I get the opportunity!
3 · Reply
Mergerbrief
Mergerbrief Sep. 4 at 12:06 PM
$VRNA / $MRK - HSR Possible Expiration MergerBrief.com
0 · Reply
FE123
FE123 Sep. 3 at 7:43 PM
$VKTX Druckenmiller last position $SWTX Buyout! Position in $VRNA Buyout! Position in $VKTX Fill in the Blank!
0 · Reply
Milanfinest
Milanfinest Sep. 3 at 6:14 PM
$VRNA pnly back to remember the old days here! 250k brang home thank u vrna team!
0 · Reply
FE123
FE123 Sep. 3 at 2:50 PM
$VKTX Druckenmiller wants his next $VRNA !
0 · Reply
ComradeKomisar
ComradeKomisar Sep. 2 at 3:49 PM
$EBS This fella was right about $VRNA May be he is right about us.
2 · Reply
MitchOnX
MitchOnX Aug. 31 at 2:21 PM
$VRNA $VRNA Verona Pharma PLC - 60 Second Analysis - August 31, 2025 #VRNA #V... https://youtu.be/bbDWVMTs76c?si=B0eimRDurqnbg0DL via @YouTube
0 · Reply